Profile picture

Doctor Silvia Cantoni

R&D Chiesi Farmaceutici S.P.A., Parma (Italy)
Membership: ESC Professional Member
Follow
Logo ESC

Contributor content

The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension
Presentation
The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension
Read more
Hemodynamic and anti-remodelling effect of the rho kinase inhibitor y-27632 in monocrotaline pulmonary arterial hypertension rat model
Presentation
Hemodynamic and anti-remodelling effect of the rho kinase inhibitor y-27632 in monocrotaline pulmonary arterial hypertension rat model
Read more

ESC 365 is supported by

novartis Explore sponsored resources